Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

By / / Finance / 1 minute of reading



im 256570
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.



Source link

About The Author

Avatar of Jana Carter
Jana Carter is a news writer and editor at Pax Press Agency. She's also a tech enthusiast, an avid reader, and an artist in her free time. She loves to write about everything from sports to art to politics—and she always strives to make her writing fun, accessible, and informative.

Start typing and press enter to search

Scroll to Top